Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
Zhao Xueqiang, co-founder of Huaxia Yingtai (Beijing) Biotechnology Co., Ltd., recently told reporters in an interview:"We have developed several autologous/universal cell therapy product pipelines, received two implied permissions for Phase I new drug clinical trials in China, obtained 'Orphan Drug' designation from the U.S. FDA for one product, and are currently conducting several 'First-in-Human' exploratory clinical trials."The company is expected to submit new drug marketing applications for 1-2 cell therapy drugs by 2026, benefiting patients in China and even globally.。”
It is reported that the pharmaceuticals and health industry is one of the "dual engines" for Beijing's innovative development. Beijing has implemented two rounds of the Medical and Health Collaborative Innovation Action Plan, providing full-chain support for industrial development.Among them, Huaxia Yingtai(Beijing)Biotechnology Co., Ltd., founded by renowned immunologist Professor Lin Xin, is developing a new generation of cell therapy products based on the self-innovated STAR-T technology platform using TCR-T technology, aiming to tackle solid tumors, hematological tumors, and autoimmune diseases."STAR-T technology has significant advantages over CAR-T, such as high recognition sensitivity, natural dual-targeting, resistance to exhaustion, and strong tumor infiltration capabilities, which have been validated in animal studies and preliminary clinical trials," introduced Zhao Xueqiang. The product pipeline of Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. aims at new targets for blood tumors and breakthroughs in solid tumors, utilizing dual-target or dual-function designs, with a layout ranging from autologous to universal types.
According to Zhao Xueqiang, currently, Huaxia Yingtai's first product, CD19/CD20 STAR-T Cell Injection, was approved in September 2022 to conduct Phase I clinical research in China for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). Another independently developed candidate product, LILRB4 STAR-T, for the treatment of acute myeloid leukemia (AML), received "Orphan Drug" designation from the U.S. FDA in December 2022 and was approved for IND to initiate Phase I clinical research in China in January 2024.Since its establishment in 2018, Huaxia Yingtai(Beijing)Biotechnology Co., Ltd. has received 420 million yuan in equity financing and multiple government project supports. It is a specialized and innovative enterprise in Beijing and a key enterprise in Beijing's Medical and Health Collaborative Innovation Action Plan.It is reported that over the past decade, the overall scale of Beijing's pharmaceuticals and healthcare industry has grown rapidly, increasing from 402.8 billion yuan in 2014 to 976.1 billion yuan in 2023, achieving a doubling effect. In the future, Beijing will advance the implementation of the third round of the "Beijing Action Plan for Accelerating Collaborative Innovation in Pharmaceuticals and Healthcare (2024-2026)," strengthening innovation and collaboration among the three medical sectors, and expanding the foundational sectors of pharmaceuticals and medical devices. It will also cultivate new productive forces, shaping new competitive advantages in emerging fields such as cell and gene therapy, digital healthcare, and synthetic biology, accelerating the leap to a trillion-yuan-scale industry.Source of the article: Xinhua Finance
